Email updates

Keep up to date with the latest news and content from BMC Medical Informatics and Decision Making and BioMed Central.

Open Access Software

GenDrux: A biomedical literature search system to identify gene expression-based drug sensitivity in breast cancer

Chiquito Crasto1, Dajie Luo2, Feliciano Yu3, Andres Forero4 and Dongquan Chen456*

Author Affiliations

1 Division of Research, Department of Genetics, Univ. of Alabama at Birmingham (UAB), USA

2 Dept of Statistics, West Virginia University (WVU), USA

3 Dept of Pediatrics, Children's Hospital, UAB, USA

4 Comprehensive Cancer Center, UAB, USA

5 Division of Preventive Medicine (DOPM), UAB, USA

6 Clinical and Translational Science Institute, WVU, USA

For all author emails, please log on.

BMC Medical Informatics and Decision Making 2011, 11:28  doi:10.1186/1472-6947-11-28

Published: 5 May 2011



This paper describes the development of a web-based tool, GenDrux, which extracts and presents (over the Internet) information related to the disease-gene-drug nexus. This information is archived from the relevant biomedical literature using automated methods. GenDrux is designed to alleviate the difficulties of manually processing the vast biomedical literature to identify disease-gene-drug relationships. GenDrux will evolve with the literature without additional algorithmic modifications.


GenDrux, a pilot system, is developed in the domain of breast cancer and can be accessed at webcite. GenDrux can be queried based on drug, gene and/or disease name. From over 8,000 relevant abstracts from the biomedical literature related to breast cancer, we have archived a corpus of more than 4,000 articles that depict gene expression-drug activity relationships for breast cancer and related cancers. The archiving process has been automated.


The successful development, implementation, and evaluation of this and similar systems when created may provide clinicians with a tool for literature management, clinical decision making, thus setting the platform for personalized therapy in the future.